This product is a first-generation cephalosporin, which has good antibacterial effect on some strains of Gram-positive cocci such as non-penicillinase-producing and penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, group A hemolytic Streptococcus, Streptococcus pneumoniae and viridans Streptococcus. Anaerobic Gram-positive bacteria are mostly sensitive to this product, while Bacteroides fragilis is resistant to it. Methicillin-resistant Staphylococci and Enterococci are resistant to this product. The effect of this product on Gram-positive and Gram-negative bacteria is similar to that of cephalexin. This product has a certain effect on Neisseria gonorrhoeae, and is also active against enzyme-producing Neisseria gonorrhoeae; its activity against Haemophilus influenzae is poor.

This product is a broad-spectrum antifungal drug. Its mechanism of action is to inhibit the synthesis of cell membranes. It has antibacterial effects on dermatophytes and Candida.

This product is a broad-spectrum antifungal drug. Its mechanism of action is to inhibit the synthesis of cell membranes. It has antibacterial effects on dermatophytes and Candida.

This product is a broad-spectrum antifungal drug. Its mechanism of action is to inhibit the synthesis of cell membranes. It has antibacterial effects on dermatophytes and Candida.

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. Its effect on Gram-positive bacteria is slightly worse than that of erythromycin, but its effect on Legionella pneumophila is stronger than that of erythromycin. Its antimicrobial effect on Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P position), blocking the transfer RNA (t-RNA) from binding to the P position, and also blocking the transfer of the polypeptide chain from the acceptor position (A position) to the P position, thereby inhibiting bacterial protein synthesis.

This product is a semi-synthetic 14-membered macrolide antibiotic. The antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, and stronger than erythromycin against Legionella pneumophila. The antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor ("P" position), blocking the transfer RNA (t-RNA) binding to the "P" position, and also blocking the transfer of the polypeptide chain from the acceptor position ("A" position) to the "P" position, thereby inhibiting bacterial protein synthesis.

1. 4-hydropyridine calcium ion antagonists reduce the entry of calcium ions into cells; specifically act on myocardial cells, coronary arteries and smooth muscle cells of peripheral resistance vessels; dilate coronary arteries, reduce coronary artery smooth muscle tension, and prevent vascular spasm; increase blood flow in narrow blood vessels, improve oxygen supply, and reduce peripheral resistance and blood pressure; short-term or long-term use can increase the excretion of sodium and water, and has a significant antihypertensive effect on patients with hypertension.